In whole genome sequencing analyses of high-risk neuroblastoma, MYCN amplifications (37%), TERT rearrangements (23%), and recurrent ATRX deletions (11%) were identified [18,118,119]. This evidence concerns the gene MYCN and neuroblastoma.